Saidal Group signed a memorandum of understanding (MoU) on Sunday with the Swiss group Bioexpress Therapeutics, in a new step reflecting both parties’ desire to strengthen international cooperation in the pharmaceutical industry and biotechnology sectors.
The MoU aims to establish a strategic cooperation framework primarily focused on training and skill development in biotechnology, paving the way for a gradual and organized technology transfer process. This partnership also seeks to create favorable conditions for the local production of biotechnological products, enhancing national capabilities and supporting the goal of achieving health sovereignty.
Through this agreement, Saidal Group reaffirms its commitment to supporting innovation, developing national expertise, and integrating advanced technologies, while expanding its network of strategic partnerships with leading international actors in the pharmaceutical and biotherapy sectors.
Reference: link
